Onabotulinumtoxina in migraine: A review of the literature and factors associated with efficacy

Jason C. Ray, Elspeth J. Hutton, Manjit Matharu

Research output: Contribution to journalReview ArticleResearchpeer-review

4 Citations (Scopus)

Abstract

The efficacy of onabotulinumtoxinA (OnaB-A) as a preventative treatment for chronic migraine, emerging fortuitously from clinical observation is now supported by class one evidence and over two decades of real-world clinical data. There is still limited ability to predict a clinically meaningful response to OnaB-A for individual patients, however. This review summarises briefly the proposed mechanism of OnaB-A in chronic migraine, the literature of predictors of clinical response, and recent developments in the field.

Original languageEnglish
Article number2898
Number of pages13
JournalJournal of Clinical Medicine
Volume10
Issue number13
DOIs
Publication statusPublished - 1 Jul 2021

Keywords

  • Botulinum toxin
  • Migraine
  • Predictors of efficacy

Cite this